Clinical Trial Update: Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updates ipatasertib in combination with chemotherapy/immunotherapy regimens for metastatic triple-negative breast cancer; completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• CARBOPLATIN (Carboplatin)
• Capecitabine (capecitabine)
• PACLITAXEL (PACLITAXEL)
• ipatasertib (ipatasertib)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-21